Reproductive fitness advantage of BCR-ABL expressing leukemia cells

Cancer Letters

Volumn 294, Issue 1, 2010, Pages 43-48

  Traulsen, Arne ^a   Pacheco, Jorge M ^b,c   Dingli, David ^d  

^a MAX PLANCK INSTITUTE FOR EVOLUTIONARY BIOLOGY   (Germany)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

^d MAYO CLINIC   (United States)

Author keywords

BCR ABL; Cancer dynamics; Cancer evolution; Mutation fitness; Oncogenes

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ARTICLE; CANCER STEM CELL; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG PROTEIN BINDING; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; IN VIVO STUDY; LEUKEMOGENESIS; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL DIVISION; CELL MOVEMENT; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC FITNESS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, GENETIC; MUTATION; ONCOGENES; PHENOTYPE; PIPERAZINES; PROBABILITY; PYRIMIDINES;

EID: 77952970855     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.020     Document Type: Article

References (38)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
3. Tomlinson I., Bodmer W. Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nat. Med. 1999, 5:11-12.
4. Cairns J. Mutation selection and the natural history of cancer. Nature 1975, 255:197-200.
5. Cairns J. Mutation and cancer: the antecedents to our studies of adaptive mutation. Genetics 1998, 148:1433-1440.
6. Beerenwinkel N., Antal T., Dingli D., Traulsen A., Kinzler K.W., Velculescu V.E., Vogelstein B., Nowak M.A. Genetic progression and the waiting time to cancer. PLoS Comput. Biol. 2007, 3:e225.
7. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
8. Zhao R.C., Jiang Y., Verfaillie C.M. A model of human p210(BCR/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. Blood 2001, 97:2406-2412.
9. Marley S.B., Davidson R.J., Goldman J.M., Gordon M.Y. Combination of interferon alpha with either Ara-C or ATRA in vitro reduces the selective action of interferon against CML CFU-GM. Leukemia 2000, 14:1396-1400.
10. Marley S.B., Davidson R.J., Goldman J.M., Gordon M.Y. Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. Brit. J. Haematol. 2002, 116:162-165.
11. Marley S.B., Lewis J.L., Goldman J.M., Gordon M.Y. Abnormal kinetics of colony formation by erythroid burst-forming units (BFU-E) in chronic myeloid leukaemia. Brit. J. Haematol. 1996, 93:878-883.
12. Dingli D., Traulsen A., Pacheco J.M. Chronic myeloid leukemia: origin, development, response to therapy, and relapse. Clin. Leukemia 2008, 2:133-139.
13. Dingli D., Traulsen A., Pacheco J.M. Compartmental architecture and dynamics of hematopoiesis. PLoS ONE 2007, 2:e345.
14. Donohue D.M., Reiff R.H., Hanson M.L., Betson Y., Finch C.A. Quantitative measurement of the erythrocytic and granulocytic cells of the marrow and blood. J. Clin. Invest. 1958, 37:1571-1576.
15. Cronkite E.P., Fliedner T.M. Granulocytopoiesis. New Engl. J. Med. 1964, 270:1403-1408. CONCL.
16. Cronkite E.P., Fliedner T.M. Granulocytopoiesis. New Engl. J. Med. 1964, 270:1347-1352. (CONTD).
17. Araten D.J., Nafa K., Pakdeesuwan K., Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc. Natl. Acad. Sci. USA 1999, 96:5209-5214.
18. Vaziri H., Dragowska W., Allsopp R.C., Thomas T.E., Harley C.B., Lansdorp P.M. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc. Natl. Acad. Sci. USA 1994, 91:9857-9860.
19. Rufer N., Brummendorf T.H., Kolvraa S., Bischoff C., Christensen K., Wadsworth L., Schulzer M., Lansdorp P.M. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J. Exp. Med. 1999, 190:157-167.
20. Gordon M.Y., Blackett N.M. Routes to repopulation - a unification of the stochastic model and separation of stem-cell subpopulations. Leukemia 1994, 8:1068-1072. (discussion 1072-3).
21. Abkowitz J.L., Catlin S.N., Guttorp P. Evidence that hematopoiesis may be a stochastic process in vivo. Nat. Med. 1996, 2:190-197.
22. Dingli D., Traulsen A., Michor F. (A) Symmetric stem cell replication and cancer. PLoS Comput. Biol. 2007, 3:e53.
23. Primo D., Sanchez M.L., Espinosa A.B., Tabernero M.D., Rasillo A., Sayagues J.M., Gonzalez M., Hernandez J.M., Orfao A. Lineage involvement in chronic myeloid leukaemia: comparison between MBCR/ABL and mBCR/ABL cases. Brit. J. Haematol. 2006, 132:736-739.
24. Holyoake T.L., Jiang X., Drummond M.W., Eaves A.C., Eaves C.J. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia 2002, 16:549-558.
25. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2:561-566.
26. Huntly B.J., Shigematsu H., Deguchi K., Lee B.H., Mizuno S., Duclos N., Rowan R., Amaral S., Curley D., Williams I.R., Akashi K., Gilliland D.G. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004, 6:587-596.
27. Lenaerts T., Pacheco J.M., Traulsen A., Dingli D. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica 2009, 10.3324/haematol.2009.015271.
28. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., Nowak M.A. Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267-1270.
29. Roeder I., Horn M., Glauche I., Hochhaus A., Mueller M.C., Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 2006, 12:1181-1184.
30. M. Ichimaru, T. Ishimaru, M. Mikami, Y. Yamada, T. Ohkita, Incidence of leukemia in a fixed cohort of atomic bomb survivors and controls, Hiroshima and Nagasaki October 1950-December 1978, Technical Report RERF TR 13-81, Radiation Effects Research Foundation, Hiroshima, 1981.
31. Dingli D., Pacheco J.M., Traulsen A. Multiple mutant clones in blood rarely coexist. Phys. Rev. E Stat. Nonlin. Soft. Matter Phys. 2008, 77:021915.
32. Loeffler M., Pantel K., Wulff H., Wichmann H.E. A mathematical model of erythropoiesis in mice and rats. Part 1: structure of the model. Cell Tissue Kinet. 1989, 22:13-30.
33. Colijn C., Fowler A.C., Mackey M.C. High frequency spikes in long period blood cell oscillations. J. Math. Biol. 2006, 53:499-519.
34. Haeno H., Levine R.L., Gilliland D.G., Michor F. A progenitor cell origin of myeloid malignancies. Proc. Natl. Acad. Sci. USA 2009, 106:16616-16621.
35. Brummendorf T.H., Holyoake T.L., Rufer N., Barnett M.J., Schulzer M., Eaves C.J., Eaves A.C., Lansdorp P.M. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000, 95:1883-1890.
36. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., Cervantes F., Hochhaus A., Powell B.L., Gabrilove J.L., Rousselot P., Reiffers J., Cornelissen J.J., Hughes T., Agis H., Fischer T., Verhoef G., Shepherd J., Saglio G., Gratwohl A., Nielsen J.L., Radich J.P., Simonsson B., Taylor K., Baccarani M., So C., Letvak L., Larson R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl. J. Med. 2006, 355:2408-2417.
37. Marley S.B., Gordon M.Y. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. Clin. Sci. (London) 2005, 109:13-25.
38. Peng B., Lloyd P., Schran H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet. 2005, 44:879-894.